Merck & Co., Inc. $MRK Shares Acquired by Renaissance Investment Group LLC

Renaissance Investment Group LLC raised its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 184.6% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 22,877 shares of the company’s stock after buying an additional 14,840 shares during the period. Renaissance Investment Group LLC’s holdings in Merck & Co., Inc. were worth $3,324,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the business. Bullseye Investment Management LLC bought a new position in shares of Merck & Co., Inc. in the second quarter valued at $27,000. Curry Webb Wealth Management LLC acquired a new stake in shares of Merck & Co., Inc. during the 3rd quarter valued at $29,000. Horizons Wealth Management acquired a new stake in shares of Merck & Co., Inc. during the 3rd quarter valued at $30,000. Graney & King LLC boosted its stake in shares of Merck & Co., Inc. by 400.0% during the 2nd quarter. Graney & King LLC now owns 250 shares of the company’s stock worth $32,000 after acquiring an additional 200 shares in the last quarter. Finally, Montgomery Financial Services LLC bought a new stake in shares of Merck & Co., Inc. during the 2nd quarter worth $41,000. 76.07% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, EVP Richard R. Deluca sold 11,699 shares of Merck & Co., Inc. stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $131.63, for a total transaction of $1,539,939.37. Following the transaction, the executive vice president owned 110,167 shares in the company, valued at approximately $14,501,282.21. The trade was a 9.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP David Williams sold 52,847 shares of Merck & Co., Inc. stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $128.77, for a total value of $6,805,108.19. Following the transaction, the executive vice president owned 31,716 shares in the company, valued at $4,084,069.32. This represents a 62.49% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 228,238 shares of company stock valued at $29,977,783. 0.17% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on MRK shares. Guggenheim lifted their target price on Merck & Co., Inc. from $170.00 to $171.00 and gave the stock a “buy” rating in a report on Friday. JPMorgan Chase & Co. upped their target price on Merck & Co., Inc. from $165.00 to $175.00 and gave the company an “overweight” rating in a report on Friday. Jefferies Financial Group upped their target price on Merck & Co., Inc. from $152.00 to $175.00 and gave the company a “buy” rating in a report on Thursday, August 20th. The Goldman Sachs Group increased their price target on Merck & Co., Inc. from $140.00 to $160.00 and gave the company a “buy” rating in a research report on Friday, August 21st. Finally, Rothschild & Co Redburn lifted their price target on Merck & Co., Inc. from $140.00 to $145.00 and gave the stock a “buy” rating in a research note on Monday, July 6th. Seventeen research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $156.08.

Merck & Co., Inc. Stock Up 2.3%

Shares of NYSE:MRK opened at $149.75 on Friday. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.10 and a current ratio of 1.32. The company has a market cap of $369.46 billion, a PE ratio of 154.38, a price-to-earnings-growth ratio of 6.38 and a beta of 0.21. Merck & Co., Inc. has a 52 week low of $82.01 and a 52 week high of $156.92. The firm has a 50 day simple moving average of $146.90 and a 200 day simple moving average of $126.69.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Thursday, October 29th. The company reported $2.49 EPS for the quarter, topping analysts’ consensus estimates of $2.09 by $0.40. Merck & Co., Inc. had a net margin of 3.64% and a return on equity of 16.56%. The firm had revenue of $18.09 billion during the quarter, compared to analyst estimates of $17.33 billion. During the same quarter last year, the business posted $2.58 EPS. The company’s revenue was up 4.7% on a year-over-year basis. As a group, research analysts expect that Merck & Co., Inc. will post 2.80 earnings per share for the current year.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Strong Q3 results and raised outlook: Merck reported adjusted earnings of $2.49 per share versus the $2.09 analyst consensus, while revenue rose 4.7% year over year to $18.09 billion, ahead of estimates. Management raised its 2026 sales and adjusted-profit outlook, providing the main catalyst for the stock’s advance. Merck tops quarterly estimates and hikes profit outlook
• Positive Sentiment: Growth beyond Keytruda: Keytruda, including the newer Qlex formulation, delivered stronger-than-expected sales, while WINREVAIR continued to expand rapidly. Newer product launches are helping offset losses from generic competition and support Merck’s growth outlook. Merck Q3 earnings call highlights pipeline progress and raised outlook
• Positive Sentiment: Pipeline progress: Positive Phase 3 endometrial-cancer data for Keytruda and sacituzumab tirumotecan, along with FDA priority review for the latter, strengthens confidence in Merck’s oncology pipeline and its ability to address future revenue pressure. Merck Phase 3 endometrial cancer data and FDA review
• Positive Sentiment: Supportive analyst action: Guggenheim raised its price target to $171 and maintained a buy rating, indicating additional potential upside based on the earnings and pipeline outlook.

About Merck & Co., Inc.

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck’s principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.